HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Reuters

Jul 23, 2025

HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553724867"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553724867\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553724867?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553724867","market":"nz","top_or_hot":-1,"title":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL7Kc24N:1","article_id":"2553724867","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553724867","pubTimestamp":1753274241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","02142":"和铂医药-B","BK1161":"生物科技","BK1583":"高瓴概念"},"translate_title":"HBM Holdings Ltd.宣布长效抗TSLP抗体治疗哮喘的全球2期POLARIS试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    \n\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}